Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery - the GSK experience.
Drug Discov Today
; 16(15-16): 646-53, 2011 Aug.
Article
de En
| MEDLINE
| ID: mdl-21601652
ABSTRACT
Drug toxicity is a major cause of late-stage product attrition. During lead identification and optimization phases little information is typically available about which molecules might have safety concerns. A system was built linking chemistry, preclinical and human safety information, enabling scientists to lever safety knowledge across multiple disciplines. The system consists of a data warehouse with chemical structures and chemical and biological properties for â¼80000 compounds and tools to access and analyze clinical data, toxicology, in vitro pharmacology and drug metabolism data. Tapping into this safety knowledge enables rapid clinically focused risk assessments of drug candidates. Use of this strategy adds value to the drug discovery process at GSK via efficient triage of compounds based on their potential for toxicity.
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Conception de médicament
/
Industrie pharmaceutique
/
Découverte de médicament
Type d'étude:
Etiology_studies
/
Risk_factors_studies
Limites:
Animals
/
Humans
Langue:
En
Journal:
Drug Discov Today
Sujet du journal:
FARMACOLOGIA
/
TERAPIA POR MEDICAMENTOS
Année:
2011
Type de document:
Article
Pays d'affiliation:
États-Unis d'Amérique